Final height and body mass index in adult survivors of childhood acute lymphoblastic leukemia treated without cranial radiotherapy: a retrospective longitudinal multicenter Italian study

Table 1 Characteristics of treatment protocols

Protocols	87	8801	8802	8805	9101	9102	9501 – 9502 armA	9502 armB	2000
PDN	2500	1830	1830	150	2030	1970	1970	1620	1910
VCR	20.5	9	12	9	12	12	12	15	18
DNM	180	160	160	-	120	120	-	120	120
MTX IT	٧	٧	٧	٧	٧	٧	٧	٧	٧
L-ASP	5400	80000	80000	-	80000	80000	120000	120000	80000
6-MP	6000	29920	25900	-	5100	28920	27350	6710	6830
MTX IV	180	1540	1500	30	1488	1500	1488	1500	1500
CPM	-	2000	3000	1600	1000	3000	1000	3000	2500
DESA	-	189	249	300	249	249	261	297	409
6-TG	-	900	900	-	840	840	780	780	780
ARA-C	-	600	600	900	600	1800	600	1600	600-1800
IFO	-	-	-	12000	-	-	-	-	-
VM-26	-	-	-	600	-	-	-	-	-
ADM	-	60	120	150	120	120	120	120	60-120
Num. patients exposed	2	1	2	4	5	28	2	57	6

Legend: Drugs are expressed as cumulative dose (mg/mq). PDN, prednisolone; VCR, vincristine; DNM, daunorubicin; MTX, metotrexate; IT, intrathecal; ٧ included; L-ASP; L-asparaginase (UI/mq); 6-MP, 6-mercatopurine; IV, intravenously; CPM, cyclophosphamide; DESA, dexamethasone; 6-TG, 6-thioguanine; ARA-C, cytosine arabinoside.; IFO, ifosfamide; VM-26,teniposide; ADM, adriamycin.

ISSN: 1471-2431